LivaNova PLC
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
LIVN$92.61+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Definitions
In this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, the following terms and abbreviations have the meanings listed below. “LivaNova” and the “Company” refer to LivaNova PLC and its consolidated subsidiaries.
| Abbreviation | Definition |
|---|---|
| 2015 Plan | LivaNova PLC 2015 Incentive Award Plan |
| 2015 Plan Amendment | Amendment No. 2 to the LivaNova PLC 2015 Incentive Award Plan |
| 2021 First Lien Credit Agreement | First Lien Credit Agreement between LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, entered into on August 13, 2021 |
| 2023 Form 10-K | LivaNova PLC’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024 |
| 2024 Restructuring Plan | A plan, initiated during the first quarter of 2024, to enhance LivaNova’s focus on its core Cardiopulmonary and Neuromodulation segments |
| 2025 Capped Calls | Privately-negotiated capped call transactions entered into with certain financial institutions |
| 2025 Notes | $287.5 million aggregate principal amount 3.00% unsecured cash exchangeable senior notes due 2025 by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova USA on June 17, 2020 |
| 2025 Notes Repurchase Transaction | Repurchase of $230.0 million aggregate principal amount of the 2025 Notes in privately-negotiated transactions from proceeds from the issuance of the 2029 Notes |
| 2029 Capped Calls | Privately-negotiated capped call transactions entered into with certain financial institutions |
| 2029 Notes | $345.0 million aggregate principal amount 2.50% unsecured convertible senior notes due 2029 by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova PLC on March 8, 2024 |
| A&R 2022 Plan | Amended and Restated LivaNova PLC 2022 Incentive Award Plan |
| A&R 2022 Plan Amendment | Amendment No. 1 to the Amended and Restated LivaNova PLC 2022 Incentive Award Plan |
| ACS | Advanced Circulatory Support |
| ALung | ALung Technologies, Inc. |
| AOCI | Accumulated other comprehensive income (loss) |
| Barclays | Barclays Bank Ireland PLC |
| Capped Call Transactions | The 2025 Capped Calls and the 2029 Capped Calls |
| CEO | Chief Executive Officer |
| CFO | Chief Financial Officer |
| CMS | The U.S. Centers for Medicare & Medicaid Services |
| CODM | Chief Operating Decision Maker |
| Court of Appeal | Court of Appeal in Milan |
| Delayed Draw Term Facility | $50.0 million delayed draw term facility under the 2021 First Lien Credit Agreement resulting from the Incremental Facility Amendment No. 2 |
| DRE | Drug-resistant epilepsy |
| DTD | Difficult-to-treat depression |
| ECJ | European Court of Justice |
| Embedded Derivatives | The bifurcated embedded derivatives associated with the 2025 Notes and 2029 Notes, collectively |
| Exchange Act | U.S. Securities Exchange Act of 1934, as amended |
| FX | Foreign currency exchange rate |
| HLM | Heart-lung machine |
| ImThera | ImThera Medical, Inc., acquired by LivaNova in 2018, a company developing an implantable neurostimulation device system for the treatment of obstructive sleep apnea |
| Incremental Facility Amendment No. 2 | An incremental facility amendment to the 2021 First Lien Credit Agreement, dated July 6, 2022 |
| Abbreviation | Definition |
|---|---|
| Incremental Facility Amendment No. 3 | An incremental facility amendment to the 2021 First Lien Credit Agreement, dated March 8, 2024 |
| Initial Term Facility | $300.0 million term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2 |
| ISIN | National Inspectorate for Nuclear Safety and Radiation Protection, a sub-body of the Italian Ministry of Economic Development |
| LivaNova PLC | A public limited company organized under the laws of England and Wales on February 20, 2015 |
| LivaNova USA | LivaNova USA, Inc. |
| LSM | LivaNova Site Management S.r.l. |
| MDL | Federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania |
| MedTech | Medical technology |
| Nasdaq | Nasdaq Global Select Market |
| OCI | Other comprehensive income (loss) |
| Option Counterparties | Certain financial institutions with whom LivaNova USA or LivaNova PLC, as applicable, has entered into the 2025 Capped Calls and 2029 Capped Calls |
| OSA | Obstructive sleep apnea |
| OSPREY clinical trial | LivaNova’s clinical trial, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation” |
| Pillar Two | Organisation for Economic Co-operation and Development Global Anti-Base Erosion Model Rules (Pillar Two) |
| Public Administrations | The Italian Ministry of the Environment and other Italian government agencies |
| R&D | Research and Development |
| Report | This Quarterly Report on Form 10-Q |
| RSUs | Restricted stock units |
| SARs | Stock appreciation rights |
| SEC | U.S. Securities and Exchange Commission |
| Securities Act | U.S. Securities Act of 1933, as amended |
| SG&A | Selling, general, and administrative expenses |
| ShiraTronics | ShiraTronics, Inc., a company developing an implantable neuromodulation therapy device for the treatment of chronic migraine attacks |
| SNIA | SNIA S.p.A. |
| SNIA Litigation Guarantee | A first demand bank guarantee of €270.0 million in connection with the SNIA environmental litigation |
| Sorin | Sorin S.p.A. |
| Term Facilities | The Initial Term Facility, together with the Delayed Draw Term Facility |
| U.S. | United States of America |
| U.S. GAAP | Generally Accepted Accounting Principles in the U.S. |
| UK | United Kingdom |
| UK Act | Finance (No. 2) Act 2023 |
| USD | U.S. dollar |
| VNS Therapy | LivaNova Vagus Nerve Stimulation Therapy |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.